CA 180-372, AALL1122 A Phase 2, Multi-Center, Historically Controlled Study of Dasatinib added to Standard Chemotherapy for Relapsed/Refractory Ph+ALL

Grant

Date/time Interval

  • June 30, 2017 - July 1, 2018
  • Total Award Amount

  • 0.00
  • Direct Costs

  • 0.00
  • Sponsor Award Id

  • Contributor

  • Kutny M.D., Matthew   Principal Investigator